M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.64
    -0.04 (-0.52%)

    Market Cap: $2.83B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(13/24)
    Avg Surprise
    -229.90%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.36 - $-0.04
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.05+45.5%
    60d ago$-0.05+48.7%
    30d ago$-0.05+48.7%
    7d ago$-0.05+48.7%
    Current$-0.09
    Revenue Consensus
    $44M
    Range$42M - $46M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range$-0.57 - $0.10
    8 analysts
    Revenue Consensus
    $65M
    Range$64M - $67M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.00---
    Sep 26EST
    		-$-0.09---
    Jun 26
    Reported Aug 6
    		$-0.07$-0.07+0.00%Beat+12.5%
    Mar 26
    Reported May 7
    		$0.01N/A+120.00%Beat+112.5%
    Dec 25
    Reported Feb 25
    		$-0.04$-0.07+43.02%Beat+33.3%
    Sep 25
    Reported Nov 6
    		$-0.08$-0.08+0.00%Beat-300.0%
    Jun 25
    Reported Aug 11
    		$-0.08$-0.07-14.29%Miss-43.4%
    Mar 25
    Reported May 12
    		$-0.08$-0.07-14.29%Miss-300.0%
    Dec 24
    Reported Mar 18
    		$-0.06$-0.04-49.63%Miss-700.0%
    Sep 24
    Reported Nov 7
    		$-0.02$-0.01-100.00%Miss-100.0%
    Jun 24
    Reported Aug 7
    		$-0.06$-0.00-6875.00%Miss-11.6%
    Mar 24
    Reported May 8
    		$-0.02$-0.03+33.33%Beat-166.7%
    Dec 23
    Reported Feb 22
    		$0.01$-0.01+200.00%Beat-97.1%
    Sep 23
    Reported Nov 7
    		$-0.01$0.01-200.00%Miss-102.7%
    Jun 23
    Reported Aug 7
    		$-0.05$0.01-600.00%Miss-109.3%
    Mar 23
    Reported May 8
    		$0.03$0.04-25.00%Miss-94.4%
    Dec 22
    Reported Feb 22
    		$0.35$0.34+2.94%Beat-22.2%
    Sep 22
    Reported Nov 2
    		$0.37$0.33+12.12%Beat+311.1%
    Jun 22
    Reported Aug 4
    		$0.54$0.45+20.00%Beat+22.7%
    Mar 22
    Reported May 5
    		$0.54$0.44+22.73%Beat+2600.0%
    Dec 21
    Reported Feb 23
    		$0.45$0.38+18.42%Beat+246.2%
    Sep 21
    Reported Nov 10
    		$0.09$0.17-47.06%Miss+550.0%
    Jun 21
    Reported Aug 10
    		$0.44$0.02+2100.00%Beat-
    Mar 21
    Reported May 10
    		$0.02N/A-71.43%Miss-
    Dec 20
    Reported Mar 2
    		$0.13$0.11+18.18%Beat-
    Sep 20
    Reported Nov 23
    		$-0.02N/A-111.76%Miss-

    Key Metrics

    Valuation
    P/E Ratio-42.44EV/EBITDA1.77x
    Price/FCF-32.21xFCF Yield-3.11%
    Profitability
    Profit Margin-37.10%Operating Margin-29.40%
    ROE-33.10%ROIC180.25%
    Financial Health
    Debt/Equity0.72xInterest Coverage13.86x
    Current Ratio4.05xQuick Ratio2.98x
    Trading Statistics
    Beta0.58Avg Volume4.50M
    52-Week High$9.4252-Week Low$2.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.99
    SMA 20$7.00
    SMA 50$6.65
    SMA 200$4.42
    EMA 10$7.81
    EMA 20$7.37
    EMA 50$6.61
    EMA 200$4.83

    MACD

    Line: 0.52Signal: 0.42Hist: 0.10

    ADX

    ADX: 37.5+DI: 35.8-DI: 24.2

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down36.0
    PSAR$7.08

    Bollinger Bands

    Upper Band$9.47
    Lower Band$4.54
    %B Position7046%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    56.1

    Momentum Oscillators

    Stoch %K60.8
    Stoch %D72.9
    Williams %R-45.8
    ROC (10d)34.5%
    Momentum1.96
    CCI (20d)38.4
    MFI (14d)66.8

    Volatility Measures

    ATR (14d)$0.53(7.0%)
    StdDev (20d)1.23
    Hist Vol119.1%(High)

    Volume Flow

    VWAP$7.63
    OBV10.3M
    AD Line19.0M
    CMF (20d)0.154

    Volume Metrics

    Avg Vol (20d)4.6M
    Vol Ratio1.2x
    VWMA (20d)$7.61

    Pivot Points

    R3$8.55
    R2$8.36
    R1$8.02
    Pivot Point$7.83
    S1$7.49
    S2$7.30
    S3$6.96

    Advanced Oscillators

    TSI28.84
    Ultimate Osc49.1
    KST189.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$51.44M$65.84M$49.87M$41.63M$47.40M$46.85M$56.56M$69.03M$69.42M$64.18M$74.14M$66.86M
    Cost of Revenue$30.79M$32.14M$37.02M$35.98M$39.63M$39.13M$37.17M$36.79M$38.58M$38.34M$35.11M$36.69M
    Gross Profit$20.65M$33.70M$12.84M$5.66M$7.77M$7.72M$19.39M$32.23M$30.84M$25.84M$39.03M$30.18M
    Operating Expenses$35.74M$35.86M$71.64M$46.69M$74.05M$56.89M$57.09M$197.85M$44.28M$44.70M$46.18M$45.60M
    R&D$3.70M$3.89M$3.79M$3.84M$4.88M$4.89M$4.56M$4.70M$4.92M$5.03M$4.59M$4.35M
    SG&A$32.07M$29.09M$31.58M$35.40M$38.72M$39.56M$41.24M$39.09M$40.56M$40.88M$38.48M$38.86M
    Operating Income$-15,089,000$-2,158,000$-58,795,000$-41,031,000$-66,278,000$-49,162,000$-37,702,000$-165,614,000$-13,440,000$-18,861,000$-7,150,000$-15,417,000
    Interest Income$1.16M$1.87M$2.38M$2.80M$3.03M$3.23M$6.04M$7.07M$7.09M$7.21M$7.46M$7.43M
    Interest Expense$7.82M$5.75M$6.55M$6.84M$6.82M$6.78M$14.45M$13.63M$11.94M$10.86M$15.40M$11.64M
    Income Before Tax$-21,802,000$-6,528,000$-63,009,000$-45,149,000$-74,125,000$-52,691,000$-46,074,000$-172,144,000$-20,855,000$-22,409,000$656.19M$-20,563,000
    Income Tax Expense$-171,000$-151,000$6,000$-92,000$-4,288,000$162,000$-7,000$311,000$-2,435,000$271,000$766.17M$-5,461,000
    Net Income$-21,631,000$-6,377,000$-63,015,000$-45,057,000$-69,837,000$-52,853,000$-46,067,000$-172,455,000$-18,420,000$-22,680,000$-109,982,000$-15,102,000
    EBITDA$-1,734,000$10.33M$-43,702,000$-25,260,000$-54,954,000$-34,228,000$-22,515,000$-150,749,000$-711,000$-4,262,000$677.85M$-2,524,000
    EBIT$-15,141,000$-2,652,000$-58,838,000$-41,102,000$-70,340,000$-49,138,000$-37,699,000$-165,542,000$-16,002,000$-18,755,000$664.13M$-16,358,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MRVI

    News

    Why Maravai LifeSciences Holdings (MRVI) Stock Climbed After Its Latest Update

    Maravai LifeSciences Holdings (MRVI) stock climbed after reporting strong Q2 2026 earnings, which included higher sales, a smaller net loss, and reaffirmed full-year revenue guidance. While analysts see the stock as 2% overvalued with a fair value of $7.10, Simply Wall St's DCF model suggests it is undervalued with a fair value closer to $10.62. The article highlights the company's recent momentum but also notes ongoing losses and revenue volatility as potential concerns for investors.

    Sahm•8/21/26•
    Somewhat-Bullish

    12 Health Care Stocks Moving In Thursday's Intraday Session

    This article highlights 12 healthcare stocks that experienced significant movement during Thursday's intraday trading session. It details the percentage gains and losses for several companies, along with their market capitalizations. The report notes specific events like Q2 earnings releases that influenced some of these stock movements.

    Sahm•8/21/26•
    Neutral

    Maravai Lifesciences Up Over 30%, on Pace for Largest Percent Increase in Over a Year -- Data Talk

    Maravai Lifesciences Holdings, Inc. (MRVI) stock is currently trading at $7.46, marking a significant increase of 30.05%, which puts it on track for its largest single-day percentage gain in over a year. This surge would also represent its highest closing price since November 2024 and a new 52-week closing high. The company's stock has shown strong performance recently, up 129.69% year-to-date.

    Bitget•8/19/26•
    Bullish

    Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake

    A group including Hudson View Holdings LLC and JD Squared Holdings II LLC, along with individuals Stuart Feldman, Matthew Barkoff, and Joshua Wool, has reported a collective beneficial ownership of 4,009,250 shares, representing a 2.72% stake in Maravai LifeSciences Holdings, Inc. Class A common stock. This disclosure was made in a Schedule 13G/A filing, indicating that all voting and dispositive powers are held solely by the respective entities and individuals within the group, with no shared authority. The group states that its ownership is 5 percent or less of the class.

    Stock Titan•8/13/26•
    Neutral

    Maravai LifeSciences Reports Second Quarter 2026 Financial Results

    Maravai LifeSciences announced its second-quarter 2026 financial results, with total revenue increasing 9% year-over-year to $51.4 million. The company reported a net loss of $(21.6) million and Adjusted EBITDA of $8.7 million. Maravai also raised its full-year 2026 Adjusted EBITDA guidance to $33 million to $35 million, while reiterating its revenue guidance of $205 million to $215 million, driven by strong demand for its TriLink and Cygnus products and the opening of a new GMP enzyme manufacturing facility.

    BioSpace•8/7/26•
    Bullish

    Frequently Asked Questions About MRVI

    Does MRVI pay dividends?
    Maravai Lifesciences Holdings Inc (MRVI) does not currently pay a regular dividend.
    What is MRVI's market cap?
    Maravai Lifesciences Holdings Inc (MRVI) has a market capitalization of $2.83B with a current stock price of $7.64.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In